Rocket One Inc. (RKTO) Stock Price & Analysis
Rocket One Inc. (RKTO) fell 7.91% to USD 1.28 as of June 10, 2026 at 02:23 UTC, according to Nexqual real-time market data.
RKTO last closed at USD 1.39; the session ranged USD 1.19–1.42 on volume of 5,482,474 shares. Market capitalization is $28.57M, with a 52-week range of USD 0.49–2.45 (NCM). Source: Nexqual, June 10, 2026 at 02:23 UTC.
Key Statistics (as of June 10, 2026 at 02:23 UTC)
| Price | USD 1.28 |
|---|---|
| Change | ▼ 7.91% (down) |
| Previous Close | USD 1.39 |
| Open | USD 1.3 |
| Day Range | USD 1.19 – 1.42 |
| 52-Week Range | USD 0.49 – 2.45 |
| Volume | 5,482,474 shares |
| Market Cap | $28.57M |
| Exchange | NCM |
Technical Analysis (RKTO)
Nexqual's technical model rates RKTO "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:23 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 51.96 (neutral) |
| vs SMA50 | Above (USD 0.87) |
| MACD | 0.24 (positive) |
Analyst Ratings (RKTO)
Wall Street analysts rate RKTO "None", per Nexqual as of June 10, 2026 at 02:23 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (RKTO)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.16 vs est -0.1 ▼ miss |
| 2025-09-30 | USD -0.3 vs est -0.07 ▼ miss |
| 2025-06-30 | USD -0.17 vs est -0.14 ▼ miss |
| 2025-03-31 | USD -0.27 vs est -0.34 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financial Health Score (RKTO)
Nexqual rates Rocket One Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:23 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Major Backers & Investors (RKTO)
Notable institutional backers of Rocket One Inc. include Fidelity, UBS Group AG, Lido Advisors, LLC, according to Nexqual as of June 10, 2026 at 02:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.82% |
| UBS Group AG | 0.71% |
| Lido Advisors, LLC | 0.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.54% |
| Geode Capital | 0.96% |
| State Street | 0.29% |
| Northern Trust | 0.19% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
From Rocket One Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- The BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema.
- In the U.S., the FDA regulates such products under the FDCA and the Public Health Services Act and implements related regulations.
- Our policy is to actively seek the broadest intellectual property protection possible for our products, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the U.S. and elsewhere in the world.
- The license enables us to develop the platform for any indications in humans.
Partnerships
- Proceeding under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active ingredient in our NDA submission to the FDA for marketing approval.   On June 7, 2021, we entered into a sponsored research agreement with Washington University in St.
- At this time, we do not anticipate conducting any further trials in Australia.   Preclinical Development   HT-004   On November 20, 2019, we entered into a license agreement with NC State pursuant to which NC State granted us an exclusive license to HT-004 for treating allergic diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▲ 1.89% |
| ADTX | Aditxt, Inc. | USD 0.03 | ▼ 53.39% |
| PSTV | PLUS THERAPEUTICS, Inc. | USD 5.5 | ▲ 1.66% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
| ENVB | Enveric Biosciences, Inc. | USD 1.6 | ▼ 11.11% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:23 UTC. This page is informational and not investment advice.